For years, satirical late-night TV host Stephen Colbert has been running a series on his show called “Better Know a District,” which highlights one of the 435 U.S. congressional districts and its representative. While I am no Stephen Colbert, I ;am ;brutally inquisitive when it comes to the 5,000-plus listed companies on the U.S. stock exchanges.That’s why I’ve made it […]
Source: Amgen, Flickr.The biotech sector is something of a roulette wheel for investors. The chances of being right are typically against you, but if you can land a winner every now and then the rewards can multiply many times over your initial bet.A majority of the biotech sector is comprised of clinical-stage pipelines or developing product portfolios which are still […]
Source: Flickr user Mike PoreskyFew sectors offer a greater potential for risk and reward than biotechnology. It’s a sector where many companies are still in the early stages of their drug development process, but if you happen to catch a winner the returns can compound many times over.Unfortunately, the odds are stacked against biotech investors with far more drugs failing […]
Source: Wikimedia Commons .How can you know when Wall Street really loves a stock? One key sign is how many of the analysts covering the stock maintain buy ratings. Another tell-tale indicator is the price targets these analysts give for the stock. The higher the target is above the current share price, the more highly the analysts view the stock.Analysts […]
“Our life is March weather, savage and serene in one hour.” — Ralph Waldo Emerson
Substitute “biotechs” for “our life” and you have the investing version of Emerson’s quote. Depending on how binary events go, they can certainly become savage or serene quite quickly.We asked our team of experts for their top biotech picks to watch this month. Read below to […]
The biotech sector has the potential for outsized returns, but also extra risk not seen with larger pharmaceutical companies (and larger companies in general).Sometimes the easiest way to make money is to follow Warren Buffett’s advice and not lose it in the first place. We asked some of The Motley Fool’s biotech experts to weigh in on common mistakes investors […]
Source: Flickr user Ali T.Clinical stage biotech stocks can have nausea-inspiring pops-and-drops tied to news, and that makes them suitable for only the most risk-tolerant of investors. However, investors willing to accept the risk of loss can reap substantial rewards if promising pipeline drugs like Xoma Corp ‘s gevokizumab succeed in clinical trials. Since Xoma could begin reporting late stage […]
Biotech stocks can often make big moves after reporting trial data, but it’s FDA drug approvals or denials that can really make stocks in the industry pop or drop. For that reason, we asked three Motley Fool experts what FDA decisions they’re most excited about. Read on to learn which three companies and drugs are on their radar.Source: Celgene Corporation.: […]
Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis.The market’s best-performing companies last week included three healthcare stocks that won over investors with can’t-miss news. Two of these companies are highly speculative, emerging-stage biotech stocks that […]
Hepatitis C treatment has progressed by leaps and bounds in the past few years, and appears to be accelerating even more quickly now. Cure rates have increased, treatment times are plummeting, and side effects are falling away. Is now the time to jump into the biotechs researching new drugs?Industry Focus takes a look at Regulus Therapeutics and Achillion Pharmaceuticals […]
